These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32646816)

  • 1. Isotype-specific outcomes in Fc gamma receptor targeting of PspA using fusion proteins as a vaccination strategy against Streptococcus pneumoniae infection.
    Wiedinger K; McCauley J; Bitsaktsis C
    Vaccine; 2020 Jul; 38(35):5634-5646. PubMed ID: 32646816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
    Xin W; Li Y; Mo H; Roland KL; Curtiss R
    Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new candidate epitope-based vaccine against PspA PhtD of
    Shafaghi M; Bahadori Z; Barzi SM; Afshari E; Madanchi H; Mousavi SF; Shabani AA
    Front Cell Infect Microbiol; 2023; 13():1271143. PubMed ID: 38035337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen.
    Park SM; Ko HJ; Shim DH; Yang JY; Park YH; Curtiss R; Kweon MN
    J Immunol; 2008 Nov; 181(9):6447-55. PubMed ID: 18941235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
    Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
    Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
    Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
    Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
    Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.